



# Foundations of Pharmaceutical Science



# Foundations of Pharmaceutical Science



# Medicinal Chemistry

Discipline of chemistry focused on the influence of chemical structure on the delivery and pharmacological activity and metabolism of drug molecules

Related Disciplines:

- Organic Chemistry
- Biochemistry
- Pharmacology
- Pharmaceutics

# Medicinal Chemistry

## **Organic Chemistry**

- Drug Structure (Functional Groups, Stereochemistry, Physicochemical Properties)
- Structure-Activity Relationships
- Drug Design and Development

## **Biochemistry**

- Drug Transport
- Enzymes and Enzyme Activity
- Endogenous Compounds

## **Pharmacology (Pharmacodynamics)**

- Drug-Receptor Interactions and Signal Transduction
- Dose-Response (Potency, Efficacy)
- Mechanism of Action

## **Pharmaceutics (ADME; Pharmacokinetics)**

- Drug administration and absorption
- Drug distribution
- Drug metabolism and excretion

# Bioavailability

- The extent (how much) and the rate (how fast) that the active drug or drug metabolite reaches the systemic circulation/target site of action. action.
- Factors influencing bioavailability
  - **Drug structure/physiochemical properties**
  - Mode of administration
  - Formulation
  - Drug/food interactions
  - Disease state
  - Individual metabolic differences


# Chemical Structure & Pharmacologic Activity

## Pharmacophore

The minimum structural elements, functional groups and 3D arrangement of a compound necessary to cause a biological response


Non-essential parts of the molecule are referred to as auxophore(s)

Pharmacophore revealed through systematic structural modification and pharmacologic testing




*Morphine*  
(analgesic, addictive)

remove dihydrofuran  
→




*Levorphanol*  
(morphinan)  
(4X more potent analgesic,  
retains addictive properties)

↓  
remove cyclohexene



*Benzomorphan*  
(less potent than morphine  
but also less addictive)

←  
remove cyclohexane



*Meperidine*  
(10-12% less potent than morphine  
but also less addictive)



# Influence of Drug Structure

Physiochemical properties of drugs refers to the influence of functional groups on:

polarity  
ionization  
solubility  
molecular shape


These factors influence pharmacokinetics and pharmacodynamics

# Drug Polarity

Polarity of a drug refers to the extent of charge separation in a molecule.


- Factors that decrease polarity (*lipophilic*)
  - Hydrocarbon elements
- Factors that increase polarity of a drug include:  
(*hydrophilic*)
  - Formal charges (ionization)
  - Polar covalent bonds
  - Lone pair electrons
  - Hydrogen bonding

# Drug Polarity




**Both lipophilic and hydrophilic regions are present within most drug molecules**

# Drug Polarity




**Polar covalent bonds and lone pair electrons contribute to drug polarity**

# Drug Polarity



**Ionizable functional groups have the potential of contributing to polarity by generating a formal charge**

# Drug Polarity




EWG = electron-withdrawing group  
(i.e., nitro)

EWG: Stabilizes conjugate base  
increases  $K_a$ , decreases  $pK_a$

*decrease electron density around ring  
by resonance or inductive  
effects*

---



EDG = electron-donating group  
(i.e., halogens)

EDG: Destabilizes conjugate base  
decreases  $K_a$ , increases  $pK_a$



*increase electron density around ring  
by resonance or inductive  
effects*

**Substituents can influence  $pK_a$  and ionization**

# Drug Polarity

## Hydrogen bonding

H-bonds are weak interactions that occur between a H atom (bonded to an electronegative element) and the lone pair electrons of another atom within the same molecule (intramolecular) or another molecule (intermolecular).




# Polarity and Non-Covalent Bonding Interactions

- Non-covalent interactions are weak interactions between functional groups of like polarity within (intra) or between (inter) molecules
- Types of non-covalent interactions include:
  - H-bonds
  - Dipole-dipole
  - Ion-dipole
  - Hydrophobic Interactions




# Polarity and Non-Covalent Bonding Interactions

*Dipole-Dipole*




**Intermolecular**




**Intramolecular**

# Polarity and Non-Covalent Bonding Interactions

## *Ion-Dipole*




***Intermolecular***




***Intramolecular***

# Polarity and Non-Covalent Bonding Interactions

*Hydrophobic*



***Intermolecular***





***Intramolecular***

# Polarity and Water Solubility


Hydrogen bonding and ion-dipole bonding contribute to water solubility

Intermolecular H-bonding between drug functional groups and water increases water solubility

Intramolecular H-bonding or ion dipole bonding within a drug does not allow solvation by water and diminishes water solubility



# Molecular Shape




**Specific functional groups on drug bind to specific sites on receptor.  
Groups must be oriented properly to accommodate specific binding**

# Molecular Shape

- Spatial arrangement of functional groups influences physiochemical properties of drugs
- Isomers, molecules with the same molecular formula but different structural arrangement of atoms, have different physiochemical and pharmacologic properties

# Isomers



**Drug isomers have the same molecular formula with a different arrangement of atoms**


# Stereochemistry

- Two general types of stereoisomers:
  - Configurational: same structural formula except different arrangement of atoms around a chiral element in the molecule (enantiomers, diastereomers, cis/trans isomers)
  - Conformational: same structural formula different spatial arrangements due to rotation around sigma bonds



# Stereochemistry





## *Stereoisomers*



# Geometric Isomers

(cis/trans; E/Z; syn/anti)


**Differences in 3D orientation of functional groups results in different receptor binding**




# Enantiomers

- Non-superimposable mirror image isomers that arise due to the chirality of an atom or of the overall molecule. Referred to as R/S, D/L or *d/l* (dextro/levo) isomers
- Enantiomers have identical physical properties (i.e., energy, boiling point, melting point, densities, etc.) except that they rotate the plane of polarized light in different directions.
- Enantiomeric drugs do not necessarily have the same biological activity, and often have very different biological activity.
- Many drugs are sold as racemic mixtures. Racemic mixtures are 50:50 mixtures of enantiomers. FDA requires that individual enantiomers be separated and tested for biological activity even if the drug is to be sold as a racemate.

# Enantiomers




(+) propoxyphene  
(DARVON)



(-) levopropoxyphene  
(NOVRAD)

- *d*- Propoxyphene (DARVON) and *l*- propoxyphene (NOVRAD) are enantiomers
- The *d*- isomer (trade name DARVON) is a narcotic analgesic. Its *l*- enantiomer is NOVRAD which is an antitussive agent (cough suppressant)

# Enantiomers






**Differences in 3D orientation of functional groups around chiral center results in different receptor binding and different pharmacological activity**

# Diastereomers

- Diastereomers are non-superimposable, non-mirror image stereoisomers.
- Diastereomers arise in molecules with more than one chiral center or chiral element
- Diastereomers have different physical properties and different pharmacological activity

# Enantiomers & Diastereomers





**Molecules with more than one chiral center can have both enantiomers and diastereomers.**

# Conformational Isomers


- Conformers are isomers which arise due to ***rotation*** about a carbon-carbon single bond.
- Rotation around carbon-carbon single bonds may occur without any breaking of covalent bonds.
- Some conformers or conformational isomers may experience unfavorable interactions which give rise to higher energy conditions.



# Conformational Isomers





# Conformational Isomers



# Conformational Isomers

## Acetylcholine conformers




# Structure Activity Relationships (SAR)

- **Structurally specific drugs** (majority)
  - act at a specific target site such as a receptor or enzyme to produce a biological effect
  - modification of structure gives rise to modification in activity (SAR)
- **Structurally nonspecific drugs**
  - no specific site of action
  - less dependence of activity on specific drug structure




# Drug Discovery

## Structure Modification

*Endogenous*




*Synthetically Modified*



Highlighted portions of molecules illustrate auxophores

# Structure Activity Relationships (SAR)



<b>A</b>	N-acyl group required	<b>F</b>	Change of stereochemistry or esterification does not change activity
<b>B</b>	Phenyl or analog required	<b>G</b>	Oxetane or other small ring required for activity
<b>C</b>	Free hydroxyl or hydrolyzable group required	<b>H</b>	Removal of acetoxy reduces activity; other acyl analogs have improved activity
<b>D</b>	Acetoxy may be removed w/out loss of activity	<b>I</b>	Acyloxy required; substituted benzyloxy improves activity
<b>E</b>	Reduction of ketone improves activity slightly	<b>J</b>	Removal of hydroxyl reduces activity slightly



# Qualitative and Quantitative SAR

- Structural Modification of Lead Compounds (Qualitative SAR)
  - Homologation
  - Chain branching
  - Ring/chain transformations
  - Positional isomerization
  - Bioisosterism (“functional group equivalents”)
- Structural modification results in changes to pharmacodynamics (affinity, efficacy, potency) and pharmacokinetics (ADME)

# Structural Modification of Lead Compounds

## Homologation

- Homologation refers to progressive increases in hydrocarbon chain length (-CH<sub>2</sub> units; methyl, ethyl, propyl, etc)
- General trend is an increase followed by a decrease in activity that correlates with lipophilicity (log P)
- Increase in activity correlates with greater bioavailability. Decrease in activity occurs when reduced water solubility interferes with transport in aqueous media or formation of micelles




*micelle*



# Structural Modification of Lead Compounds

## Homologation





### ***4-Alkylresorsinol antibacterial activity***

R = n-propyl (5%); n-butyl (22%);  
n-pentyl (33%); n-hexyl (51%);  
n-heptyl (30%); n-octyl (0%)

# Structural Modification of Lead Compounds

## Chain Branching





- Branching imposes steric changes that affect receptor binding
- Chain branching in the aminoalkylphenothiazines promethazine and promazine results in binding to different receptors



# Structural Modification of Lead Compounds

## Ring Chain Transformations



- Ring chain transformations generally provide conformational rigidity (in the ring) and conformational flexibility (in the chain)
- Ring structures in local anesthetics enhance binding at active sites in the receptor by “holding” groups in place



# Structural Modification of Lead Compounds

## Positional Isomerization

- Altering the position of functional groups modifies receptor binding and changes pharmacokinetics
- Replacement of the catechol moiety of adrenergic agents with a resorcinol moiety enhances selectivity for  $\beta_2$ -adrenergic receptors
- Resorcinol derivatives have longer duration of action since the COMT enzyme does not metabolize these compounds







# Structural Modification of Lead Compounds

## Bioisosterism

- Bioisosteres are substituents or functional groups with steric and electronic similarities that produce broadly similar biological properties
- Two types of bioisosteres
  - Classical isosteres
  - Non-classical isosteres

# Structural Modification of Lead Compounds















## Bioisosterism

<b>Univalent</b>
CH <sub>3</sub> , NH <sub>2</sub> , OH, F, Cl Cl, PH <sub>2</sub> , SH Br, iso-Pr I, t-Bu
<b>Bivalent</b>
-CH <sub>2</sub> -, -NH-, -O-, -S-, -Se-

<b>Trivalent</b>

<b>Tetravalent</b>

<b>Ring equivalents</b>


# Structural Modification of Lead Compounds

## Bioisosterism

Table 2.10. Nonclassical Bioisosteric Replacements

Compound	Bioisosteric Replacement
	
	
	
	
	
	
	

- Non-classical Isosteres
  - substitution of substituents with groups not defined by classical isosteric terms but still bear steric and electronic similarities


# Quantitative Structure Activity Relationships

- Electronic effects (Hammett equation)
  - assigns value ( $\sigma$ ) to substituents to account for electron donating/electron withdrawing character of substituents based on inductive and resonance effects
- Lipophilicity and partition coefficient (Hansch equation)
  - assigns value (P) to molecules to account for lipophilic character
- Steric Effects (Taft Equation)
  - assigns value (E) to substituents to account for steric effects



# Quantitative Structure Activity Relationships

## Electronic effects (Hammett equation)




*EWG = electron-withdrawing group*

*EDG = electron-donating group*


# Quantitative Structure Activity Relationships

## Electronic effects (Hammett equation)

RESONANCE



INDUCTION




Both inductive and resonance effects contribute to a substituent's ability to be an EDG or EWG.

# Quantitative Structure Activity Relationships

## Electronic effects (Hammett equation)

- For meta and para substituted benzoic acids, Hammett showed a linear relationship between the ED-ability/EW ability of a substituent and the  $K_a$  of the acid (ortho- skewed by steric effects and does not correlate)



$$\frac{\log k_s}{\log k_0} = \sigma\rho$$

$\sigma$  = electronic parameter (substituent)  
 $\rho$  = reaction constant

$k_s$  = rate of ionization for substituent  
 $k_0$  = rate of ionization for H

# Quantitative Structure Activity Relationships

## Electronic effects (Hammett equation)


- The  $\sigma$  values are used to predict electron-donating and electron-withdrawing character of substituents in drugs
- The  $\sigma_{\text{meta}}$  values follow inductive trend;  $\sigma_{\text{para}}$  follow resonance trend
- Values are additive and constitutive

Substituent	Abbreviation	$\sigma_{\text{meta}}$	$\sigma_{\text{para}}$
acetamido-	AcNH-	0.21	-0.01
acetoxy-	AcO-	0.39	0.31
acetyl-	Ac-	0.38	0.50
amino-	NH <sub>2</sub> -	-0.16	-0.66
bromo-	Br-	0.39	0.23
tert-butyl-	(CH <sub>3</sub> ) <sub>3</sub> C-	-0.10	-0.20
chloro-	Cl-	0.37	0.23
cyano-	NC-	0.56	0.66
ethoxy-	EtO-	0.10	-0.24
ethyl-	Et-	-0.07	-0.15
fluoro-	F-	0.34	0.06
hydrogen	H-	0.00	0.00
hydroxy-	HO-	0.12	-0.37
methoxy-	MeO-	0.12	-0.27
methyl-	Me-	-0.07	-0.17
nitro-	NO <sub>2</sub> -	0.71	0.78
phenyl-	Ph-	0.06	-0.01
trifluoromethyl	F <sub>3</sub> C-	0.43	0.54
trimethylamino-	(CH <sub>3</sub> ) <sub>3</sub> N <sup>+</sup> -	0.88	0.82

# Quantitative Structure Activity Relationships

## Lipophilicity and Partition Coefficient

- Partition coefficient (lipophilicity) can be correlated with biological activity
- Three models
  - linear
  - parabolic
  - bilinear



# Quantitative Structure Activity Relationships

## Lipophilicity and Partition Coefficient (Hansch)


- Lipophilic character of specific substituents can be determined and correlated with the partition coefficient
- The value  $\pi$  is used to indicate lipophilic character of specific substituents

Substituent	$\pi$
H	0.00
-CH <sub>3</sub>	0.56
-CH <sub>2</sub> CH <sub>3</sub>	1.02
-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	1.55
-C(CH <sub>3</sub> ) <sub>3</sub>	1.53
-OCH <sub>3</sub>	-0.02
-NH <sub>2</sub>	-1.23
-F	0.14
-Cl	0.71
-Br	0.86
-I	1.12
-CF <sub>3</sub>	0.88
-OH	-0.67
-COCH <sub>3</sub>	-0.55
-NHCOCH <sub>3</sub>	-0.97
-NO <sub>2</sub>	-0.8
-CN	-0.57

# Quantitative Structure Activity Relationships

## Lipophilicity and Partition Coefficient (Hansch) equation)

The partition coefficient (lipophilicity) of a compound can be calculated from  $\pi$  values of its substituents



$$\begin{aligned}\log P &= 2\pi_{\text{CH}_3} + 2\pi_{\text{CH}_2} + \pi_{\text{CH}=\text{CH}} + 2\log P_{\text{PhOH}} \\ &= 2(0.50) + 2(0.50) + 0.69 + 2(1.46) \\ &= 5.61\end{aligned}$$

*Experimental log P = 5.07*



# Quantitative Structure Activity Relationships

## Steric Effects (Taft Equation)

- Taft Equation

$-E_s$  represents the steric contribution of a particular group based on rates of hydrolysis  $\alpha$ -substituted acetates

$$E_s = \log k_{\text{xCO}_2\text{Me}} - \log k_{\text{methyl acetate}}$$




$k = \text{rate constant for acid catalyzed hydrolysis}$




# Quantitative Structure Activity Relationships

## Steric Effects (Taft Equation)

*How does changing the sterics affect potency?*



*S(+)-dexchlorpheniramine*



*R(-)-dexchlorpheniramine*

The S-enantiomer is 200 times more potent than the R as <sup>1</sup>H receptor antagonist.